|Date||Title|| || |
|22-Nov-2012||ERYTECH Pharma signs licensing and distribution agreement with Orphan Europe for GRASPA® in Europe|
|LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announced today that it has entered into a definitive agreement with Orphan Europe, part of the Recordati Group, granting Orphan Europe exclusive rights for the commercialization and distribution of GRASPA® in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe.
GRASPA®, L-asparaginase encapsulated into human erythrocytes, for the treat... |
|07-Sep-2012||ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.|
|ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.
Therapeutic proteins are often immunogenic, inducing anaphylactic reactions and/or specific immunoglobulins. Their administration is often stopped or inefficient due to neutralizing antibodies. ERYTECH’s concept consists in encapsulating the therapeutic proteins inside erythrocytes. The membrane of the erythrocytes is mo... |
|17-Jul-2012||ERYTECH Pharma announces the oral presentation of positive Phase II clinical trial results in Acute Lymphoblastic Leukemia|
|ERYTECH Pharma Announces the Oral Presentation of Positive Phase II Clinical Trial Results in Acute Lymphoblastic Leukemia
June 17, 2012 05:00 AM Eastern Daylight Time
LYON, France--(BUSINESS WIRE)--The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam (The Netherlands).
Thirty patients over 55-years old, newly diagnosed with Acut... |
|13-Jun-2012||ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency|
|ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency
June 13, 2012 08:00 AM Eastern Daylight Time
LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) t... |
|05-Jun-2012||ERYTECH Pharma receives € 7 million from OSEO to lead the TEDAC personalized medicine project in cancer|
|ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer
Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO
Leader of the collaborative project that aims to create major innovations within a unique worldwide consortium
Further optimizing a new paradigm for the treatment of fragile cancer patients through well targeted tumor starvation